Zymeworks Inc. Common Stock (ZYME)
Healthcare
Biotechnology
21.90 $
-3.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Zymeworks Inc. Common Stock (ZYME)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.2% of the shares are freely tradable; institutional investors hold 99.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
99.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
93.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
73Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 31.22 | 22,970,388 | +0.0 | 03/31/2026 |
| Rubric Capital Management LP | 9.51 | 7,000,000 | +21.7 | 03/31/2026 |
| BlackRock Inc | 6.19 | 4,553,888 | -0.9 | 03/31/2026 |
| Bvf Inc | 5.08 | 3,734,142 | -5.2 | 03/31/2026 |
| Perceptive Advisors LLC | 4.77 | 3,510,078 | +7.6 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 3.37 | 2,480,568 | -4.3 | 03/31/2026 |
| Vanguard Group Inc | 3.17 | 2,328,727 | +8.1 | 12/31/2025 |
| BNP Paribas Investment Partners SA | 2.59 | 1,908,039 | +4.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.32 | 1,705,580 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 3.43 | 2,522,736 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.